Re: Association of Black Race with Prostate Cancer-specific and Other-cause Mortality Dess RT, Hartman HE, Mahal BA, et al JAMA Oncol 2019;5:975-83 (European Urology)
Dess et al pooled individual patient-level data from the Surveillance, Epidemiology and End Results (SEER) registry, five equal-access regional medical centers within the Veterans Affairs (VA) health system, and four National Cancer Institute-sponsored Radiation Therapy Oncology Group phase 3 randomized clinical trials to evaluate prostate cancer-specific mortality (PCSM) and other-cause mortality (OCM) among black men treated for nonmetastatic prostate cancer. After adjusting for demographics, socioeconomic status, and treatment choice, the authors found that in comparison to white men, PCSM among black men was 0.5% higher in the SEER cohort at 10 yr after diagnosis, not different in the VA cohort, and 2.2% lower at 10 yr after diagnosis in the radiation randomized trials, indicating that black race was not associated with poorer PCSM [1].